2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Updates on IO in NSCLC: Does Neoadjuvant Durvalumab Add Value to Standard Chemotherapy? Is IO Atezolizumab a Feasible and Safe Addition to SABR?

89 views
September 22, 2020
Comments 0
Login to view comments. Click here to Login